Toronto Stock Exchange · Healthcare
Invest in Medexus Pharmaceuticals stock from India
Indian and foreign residents can buy Medexus Pharmaceuticals (MDP) shares directly through Paasa.
By Paasa · Updated
Medexus Pharmaceuticals at a glance
- Price
- CA$5.12+CA$0.08 (1.59%)
- Market cap
- CA$162.10M
- Day range
- CA$4.97 – CA$5.14
- P/E
- -47.45
- Dividend yield
- None
- Volume
- 22.90K
- 1 month
- -1.16%
- 6 months
- +62.54%
- YTD
- +75.95%
- 1 year
- +84.84%
- 5 years
- +68.98%
Medexus Pharmaceuticals statements, FY2022–FY2026
| Fiscal year | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | $99.3M | $108.3M | $113.1M | $108.1M | $76.7M |
| Gross profit | $54.4M | $56.6M | $59.5M | $60.0M | $37.9M |
| Operating income | $5.8M | $8.2M | $10.8M | $7.6M | −$12.4M |
| Net income | −$2.4M | $2.2M | −$214.0K | $1.2M | −$2.9M |
| Earnings per share | −$0.07 | $0.09 | −$0.01 | $0.08 | −$0.19 |
| EBITDA | $12.7M | $16.8M | $19.3M | $14.6M | $14.5M |
| Total assets | $147.3M | $171.8M | $155.7M | $161.3M | $139.2M |
| Total debt | $22.3M | $37.2M | $49.9M | $70.1M | $54.9M |
| Cash and short-term investments | $6.5M | $24.0M | $5.3M | $13.1M | $10.0M |
| Shareholders' equity | $49.0M | $52.1M | $30.3M | $22.4M | $17.8M |
| Operating cash flow | $18.9M | $24.0M | $18.7M | −$1.4M | −$1.2M |
| Free cash flow | $3.7M | $21.3M | $18.4M | −$1.8M | −$8.9M |
| Capital expenditure | −$15.2M | −$2.7M | −$266.0K | −$362.0K | −$7.7M |
Fiscal years as reported, the latest ending 31 Mar 2026. Figures in USD; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Cardiol Therapeutics | CRDL.TO | CA$2.43 | CA$280.11M |
| Planet 13 | PLTH.CN | $0.19 | $62.43M |
| Vext Science | VEXT.CN | $0.25 | $61.92M |
| Decibel Cannabis | DB.V | CA$1.57 | CA$60.40M |
| C21 Investments | CXXI.CN | $0.39 | $45.69M |
| BioNxt Solutions | BNXT.CN | $0.34 | $44.20M |
| MariMed | MRMD.CN | $0.11 | $41.92M |
| iAnthus Capital | IAN.CN | $0.01 | $34.86M |
Peers as grouped by the data provider. This is not an investment recommendation.
Analyst price targets
- Low
- —
- High
- —
- Median
- —
- Consensus
- —
Ratings: 0 buy · 1 hold · 0 sell. Consensus: Hold.
Published sell-side 12-month targets in CAD, aggregated by the data provider. They are not Paasa's view and not a forecast.
How to invest in Medexus Pharmaceuticals from India
Step 1
Open your Paasa account
KYC takes a few minutes: PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Step 2
Add funds from your Indian bank account
Remit up to $250,000 a year under the RBI's Liberalised Remittance Scheme. Your bank converts the rupees to US dollars at its rate on the day you remit, and Interactive Brokers converts the dollars to CAD when you buy.
Step 3
Search MDP and buy
Find Medexus Pharmaceuticals by name or by its ticker, MDP, and place your order.
Why invest in Medexus Pharmaceuticals from India
What Medexus Pharmaceuticals does
Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on various therapeutic areas comprising allergy, dermatology, hematology, oncology, rheumatology, and rare diseases. Medexus Pharmaceuticals operates in the Medical - Pharmaceuticals industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
Can I buy Medexus Pharmaceuticals stock from India?
Yes. Indian residents and NRIs can buy Medexus Pharmaceuticals (MDP) shares directly through Paasa. Medexus Pharmaceuticals is listed on the Toronto Stock Exchange, in the Medical - Pharmaceuticals industry. Your money leaves India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name at Interactive Brokers.
What tax do I pay in India when I sell Medexus Pharmaceuticals shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the CAD/INR rate on the day you bought and the day you sold, so the currency move is part of the gain. Paasa's capital-gains statement gives you the figures for your return.